Company Deep Dive
Business segments breakdown, earnings transcript analysis, management credibility scoring, competitive landscape, and scenario modelling.
INMB
SellHot AirINmune Bio Inc. · Healthcare · United States · $65M · Avg Vol: $803K/d
31
StockRankGet insider-trade alerts
Q
23
V
28
M
71
P/E (TTM)
—
ROE
-74.8%
D/E
0.1x
Dividend %
—
COMPANY DESCRIPTION
INmune Bio Inc. is a clinical-stage biotechnology company developing immunotherapies to treat cancer and neurodegenerative diseases by targeting the innate immune system. Its moat lies in its proprietary therapeutic platforms that modulate immune responses rather than traditional cytotoxic methods.
FINANCIAL SUMMARY (USD)
| Year | 2021 | 2022 | 2023 | 2024 | 2025 | CAGR | TTM | 2026E | 2027E | Fwd CAGR |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | — | 0.4M | 0.2M | 14.0K | 50.0K | -48.9% | — | — | 6.4M | 1027.8% |
| EPS | — | -1.52 | -1.67 | -2.11 | -1.86 | — | -0.62 | -0.55 | -0.49 | — |
| Shares | — | 17.9M | 18.0M | 22.3M | 26.6M | +48.1% | 27.8M | — | — | — |
| Debt | — | 15.3M | 10.4M | 0.4M | 1.0M | -59.3% | 1.4M | — | — | — |
| Equity | — | 60.1M | 38.1M | 32.1M | 23.5M | -26.9% | — | — | — | — |
| Op CF | — | -22.7M | -12.0M | -33.4M | -22.6M | — | -15.0M | — | — | — |
| Inv CF | -15.0M | 0 | — | 0 | -1.0M | — | — | — | — | — |
| Fin CF | — | 0.7M | -4.2M | 18.2M | 27.6M | — | — | — | — | — |
Loading 1Y...
PRICE (1Y)+30.5%
SMA 50SMA 200
Close
$2.31
RSI (14)
56.7
52W High
$2.60
From 52W High
0.9%
SCORE BREAKDOWN
Quality
23
ROIC
-84.4%8.6
ROE
-74.8%13.0
GP/Assets
0.0%9.6
Op. Margin
0.0%38.1
FCF/Assets
-73.0%4.1
Piotroski
321.9
Int. Cover
—N/A
D/E Ratio
0.07x67.5
Current Ratio
4.04x65.7
Value
28
P/E (TTM)
—N/A
EV/EBITDA
—N/A
P/FCF
—N/A
P/B
3.3x42.5
P/S
—N/A
Div Yield
—N/A
Momentum
71
52W High %
89%84.9
RS 6M
50%91.5
SMA 50/200
1.26x91.5
EPS Rev 4W
—N/A
EPS Rev 12W
—N/A
EPS Improve
+21%35.0
Q Growth
—N/A
FUNDAMENTALS
Market Cap
$65M
P/E (Forward)
-5.0x
Gross Margin
—
SECTOR PEERS
Closest peers in Healthcare, ranked by industry match, size, and score similarity. Cross-listings of INMB are excluded.
| Ticker | Company | Mkt Cap | StockRank | Signal |
|---|---|---|---|---|
| INMB | INmune Bio Inc.(you) | $65M | 31 | Sell |
| CSBR | Champions Oncology, Inc. | $68M | 30 | Sell |
| XBIT | XBiotech Inc. | $69M | 27 | Sell |
| BOLD | Boundless Bio, Inc. | $64M | 36 | Hold |
| APLM | Apollomics, Inc. | $77M | 28 | Sell |
| RNXT | RenovoRx, Inc. | $75M | 26 | Sell |
| ACRV | Acrivon Therapeutics, Inc. | $88M | 29 | Sell |
| XLO | Xilio Therapeutics, Inc. | $59M | 38 | Hold |
| BSEM | BioStem Technologies, Inc. | $63M | 39 | Hold |
| MNOV | MediciNova, Inc. | $71M | 23 | Sell |
Peer medians: ROE -30.2% · P/E 27.0x · Gross margin 58.3%